Search company, investor...
Kayentis company logo


Founded Year



Series F | Alive

Total Raised


Last Raised

$8.3M | 2 yrs ago

About Kayentis

Kayentis publishes and markets secure vertical, integrated solutions for dematerialization and intermediation of handwritten data. These solutions and services are based on a Software as a Service (SaaS) model, targeting projects which are subjected to the high level scrutiny in data sharing, security, safety and compliance.

Headquarters Location

19 bis, chemin du vieux Chêne

Meylan, 38240,


+33 (0)4 76 00 54 20

Missing: Kayentis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kayentis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kayentis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kayentis is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest Kayentis News

Kayentis Launches Platform for Decentralized Clinical Trials

May 9, 2022

Streamlined patient-centric platform alleviates many logistical hurdles in bringing key digitalization elements of clinical trials to patients’ homes. Michael Barbella, Managing Editor05.09.22 Kayentis  has released its fully integrated patient-centric platform that optimizes the management of hybrid and decentralized clinical trials (DCT). This streamlined platform alleviates many logistical hurdles in bringing key elements of the clinical trial to patients’ homes, while vastly improving how patients and sites use DCT technologies. Stakeholders in remote clinical trials gain seamless access to a wide panel of robust functionalities all within the same platform. These include various modes of data collection, such as BYOD, WebCOA, provisioned devices, and data entry by phone; as well as an easy-to-use telemedicine app. Embedded features that enable active patient engagement are also included, with options to integrate other functions in the future. “Kayentis’ new streamlined platform features make remote clinical trials much easier for patients, sites, CROs and sponsors to manage; the simplified access to options considerably reduces patient burden,” said Guillaume Juge, CEO at Kayentis. “We have been expanding our DCT services in step with the growing demand for hybrid and decentralized clinical trials. This added capacity enables our operational teams across Europe, the US and Asia to attract wider interest in our digital capabilities.”   The pandemic sped up the timeline in the transition towards DCT with patients more readily embracing remote technologies. For Kayentis, simplifying the access to and streamlining the management of functionalities is key to this digital transformation. Benefits of Kayentis’ patient-centric platform for DCT: The company considers that its fully integrated platform offers a significant advantage over using a combination of various functionalities sourced from different suppliers. Kayentis has stripped out this complexity, opting to work from the bottom up to ensure that the many functions interconnect smoothly. For sponsors, the fully integrated platform enables a single set-up of all functionalities that better facilitate sponsor lead times Sites benefit from improved flexibility in using and selectively activating any solution. Overall, the system is easier for a site investigator to manage all the features and maintain control Patients will find this fully integrated platform highly practical. They can very easily obtain a web back-up solution if, for example, they leave their device on holiday. Should they choose to conduct a remote visit, they can easily set this up with the site, and run it through the telemedicine option embedded into the same app These easy-to-use options help improve patient compliance, retention and the quality of data collected, as witnessed by Trishna Bharadia, a health advocate and patient engagement consultant for patient advisory councils and industry bodies: “During a clinical trial, patients must complete multiple study procedures, so their participation should basically be made as easy as possible. With this in mind, offering them a single digital access point for as many study procedures as possible is, of course, highly attractive,” she said. A single sign-on platform with apps for different DCT services A large set of data collection modes: BYOD, webCOA, provisioned devices, or interview mode, with flexibility to seamlessly switch to alternative data entry methods in case of need, and according to the study protocol A televisit (video chat) option for patients and site staff  Kayentis’ Media Player tool for storing training modules, user guides and educational resources (PDF, videos)  A study Participant Feedback Questionnaire module allows study patients to remotely provide feedback on their clinical trial experience Other embedded features as future options “Kayentis’ platform is applicable in all therapeutic areas, particularly complex protocols, and in all clinical trial models: traditional, virtual or hybrid clinical trials. The value in this new platform lies in its ability to expand the choice of interconnectable options, while standardizing the same enhanced user experience across multiple systems (Web, Google Android, Apple iOS),” said Martial Marcotti, product marketing director at Kayentis. Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) and decentralized clinical trial solutions, helps companies bring simplicity, efficiency and quality to the collection of clinical trial data from both patients and sites. Since 2003, Kayentis has been active in clinical development, with a strong specialization in eCOA solutions for phases II/III across a broad range of therapeutic areas. Over the years, it has developed a full range of services and is now enlarging its portfolio beyond eCOA solutions to support the post-COVID new normal of decentralized and hybrid trials. The company has conducted digital data collection for over 260 clinical trials in 79 countries (16,000 sites and 90,000 patients), employing 120 languages. It has offices in the United States (Boston), France (Grenoble) and Japan (Tokyo), and currently employs 185 staff.

Kayentis Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Kayentis Rank

Kayentis Frequently Asked Questions (FAQ)

  • When was Kayentis founded?

    Kayentis was founded in 2003.

  • Where is Kayentis's headquarters?

    Kayentis's headquarters is located at 19 bis, chemin du vieux Chêne, Meylan.

  • What is Kayentis's latest funding round?

    Kayentis's latest funding round is Series F.

  • How much did Kayentis raise?

    Kayentis raised a total of $23.16M.

  • Who are the investors of Kayentis?

    Investors of Kayentis include Extens, LBO France, Bpifrance, Innovation Capital, Lénapart and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.